J. Guerra

发表

A Web-Based Self-assessment Model for Evaluating Multidisciplinary Cancer Teams in Spain: Development and Validation Pilot Study

J. Borrás, J. Mira, M. Guilabert, 2022, Journal of medical Internet research.

Metabolic synthetic lethality: a randomized, phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

Gion, S. Morales, J. Cortés, 2019 .

Critically short telomeres and toxicity of chemotherapy in early breast cancer

M. Blasco, A. Lluch, E. Zamora, 2017, Oncotarget.

Head Cancer and Metastasic Neck. What Have WeAdvanced in the Last Years

B. Pascual, M. Pantín, D. Abad, 2018 .

A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.

C. Rodríguez-Antona, M. Apellaniz-Ruiz, J. Sepúlveda, 2019, The oncologist.

Global Approach to Neuroendocrine Tumors Neoplasms

Nadia, B. Vila, D. Abad, 2020, Microbiology, Immunology and Pathology.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

R. Colomer, J. Hornedo, S. Mourón, 2019, Breast Cancer Research.

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

A. Urruticoechea, F. Hilberg, R. Colomer, 2014, British Journal of Cancer.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

R. Colomer, J. Hornedo, S. Mourón, 2019, Breast Cancer Research.

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

F. Mulero, S. Morales, J. Cortés, 2019, Clinical Cancer Research.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

A. Carrato, F. Mulero, A. Lluch, 2016, Clinical Cancer Research.

Selective activity over a constitutively active RET‐variant of the oral multikinase inhibitor dovitinib: Results of the CNIO‐BR002 phase I‐trial

R. Salazar, M. J. Bueno, L. Lombardía, 2014, Molecular oncology.

Nutritional management of cancer patients in clinical practice in Spain: patients’ and multidisciplinary health care professionals’ perceptions

Eduardo Sánchez-Sánchez, M. Comellas, E. Cáncer, 2022, European Journal of Clinical Nutrition.

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

A. Prat, P. Villagrasa, B. González-Farré, 2021, Frontiers in Oncology.

Twelve years of global survival in squamous head and neck carcinoma. What have we advanced in these years?

B. Vila, D. Abad, J. Guerra, 2020, Otorhinolaryngology-Head and Neck Surgery.

Abstract PS12-08: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)

M. Juan, G. Nuovo, M. Coffey, 2021 .

A Web-Based Self-assessment Model for Evaluating Multidisciplinary Cancer Teams in Spain: Development and Validation Pilot Study

Mercedes Guilabert, Joan Prades, Josep M. Borras, 2021, Journal of medical Internet research.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.